The drumbeat behind next-generation biologics has been unmistakable, yet the loudest voices in today’s pipelines keep returning to a sobering reality: delivery is not polish at the finish line, it is the race itself, where fragile molecules, strict dosing windows, and hard-to-reach tissues force
Every three minutes somewhere in the world, a person with type 1 diabetes calculates a dose of insulin and still lives with the nagging reality that even perfect math will not reproduce the split-second precision of native β-cells. Clinicians point to the autoimmune destruction that erased those
Chronic HIV infection, even under suppressive antiretroviral therapy, can trap the immune system in a state of simmering alarm that never fully resolves and quietly erodes the fitness of the very T cells needed for durable control of the virus. That conundrum has intensified attention on the small
Diving into the world of virology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development. With a deep understanding of technology and innovation in the industry, Ivan has been at the forefront of groundbreaking discoveries.
The pharmaceutical landscape is on the brink of a seismic shift with the introduction of the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, a bold initiative designed to cut the review timeline for drug and biological product applications from the standard 10-12 months down to
In the rapidly evolving field of biopharmaceuticals, a groundbreaking shift is capturing the attention of industry leaders and innovators alike, promising to redefine the development of advanced therapies with remarkable potential. This transformation centers on the adoption of cell-free DNA as a
